Print this page    •   Back to Web version of article

Combivir Users Warned About Label-Switching Reports

June/July 2002

GlaxoSmithKline has received four reports of label switching on bottles of pills which should have contained Combivir, but actually contained Ziagen. Manufacturers are warning users of the medication Combivir to inspect their bottles and the tablets themselves prior to use.

While both medications are used to treat HIV infection (and are combined in Trizivir), they have very different side effects. Ziagen side effects can include hypersensitivity, which in some instances can be fatal.

Consumers with questions may call GlaxoSmithKline at (888) 825-5249.


Back to the June/July 2002 issue of Positive Living.


This article has been reprinted at The Body with the permission of AIDS Project Los Angeles (APLA).




This article was provided by AIDS Project Los Angeles. It is a part of the publication Positive Living. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art32670.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.